相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Time for a third-generation pneumococcal conjugate vaccine
Keith P. Klugman et al.
LANCET INFECTIOUS DISEASES (2021)
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Clark D. Russell et al.
LANCET MICROBE (2021)
Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework
Johan Vekemans et al.
CLINICAL INFECTIOUS DISEASES (2021)
Emergence of a new SARS-CoV-2 variant in the UK
Julian W. Tang et al.
JOURNAL OF INFECTION (2021)
Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV
Marta C. Nunes et al.
MBIO (2021)
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Heather L. Sings et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas et al.
NATURE (2021)
Evaluations of the Public Health Impact of Adult Vaccination with Pneumococcal Vaccines Should Include Reductions in All-Cause Pneumonia
Christian Theilacker et al.
CLINICAL INFECTIOUS DISEASES (2020)
Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course
Paula Peyrani et al.
CHEST (2020)
Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18
Harry Pick et al.
THORAX (2020)
Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes
Forest W. Arnold et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2020)
Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
Tolulope A. Adebanjo et al.
PEDIATRICS (2020)
Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
J. P. Sevilla et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Upper respiratory tract colonization withStreptococcus pneumoniaein adults
Adriano Arguedas et al.
EXPERT REVIEW OF VACCINES (2020)
Co-infections in people with COVID-19: a systematic review and meta-analysis
Louise Lansbury et al.
JOURNAL OF INFECTION (2020)
A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus
Feroze Ganaie et al.
MBIO (2020)
A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
Jacob Dag Berild et al.
PATHOGENS (2020)
Effect of vaccination on the use of antimicrobial agents: a systematic literature review
T. Mark Doherty et al.
ANNALS OF MEDICINE (2020)
Forecasting spatial, socioeconomic and demographic variation in COVID-19 health care demand in England and Wales
Mark D. Verhagen et al.
BMC MEDICINE (2020)
Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study
Stefan Flasche et al.
BMC MEDICINE (2020)
Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009-2017
Jose A. Suaya et al.
JOURNAL OF INFECTION (2020)
The primary care response to COVID-19 in England's National Health Service
Azeem Majeed et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2020)
Pneumococcal superinfection in COVID-19 patients: A series of 5 cases
David Cucchiari et al.
MEDICINA CLINICA (2020)
Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations
Janet Sultana et al.
EXPERT REVIEW OF VACCINES (2020)
SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections
Konstantin S. Sharov
JOURNAL OF GLOBAL HEALTH (2020)
The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development
Andrew Vyse et al.
VACCINE (2020)
Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England
James Campling et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Variation in clinical outcomes and process of care measures in community acquired pneumonia: a systematic review
H. Lawrence et al.
PNEUMONIA (2020)
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
Marina Treskova et al.
PHARMACOECONOMICS (2019)
The impact of childhood pneumococcal vaccination on hospital admissions in England: a whole population observational study
Tinevimbo Shiri et al.
BMC INFECTIOUS DISEASES (2019)
Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study
Yoon Hong Choi et al.
PLOS MEDICINE (2019)
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults
Allison Thompson et al.
VACCINE (2019)
Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy?
Rosario Martinez-Vega et al.
PLOS ONE (2019)
Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
John M. McLaughlin et al.
VACCINE (2019)
Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
Natalie Groves et al.
GENES (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies
Heather L. Sings et al.
CLINICAL INFECTIOUS DISEASES (2019)
Outbreaks of severe pneumococcal disease in closed settings in the conjugate vaccines era, 2010-2018: A systematic review to inform national guidance in the UK
Zahin Amin-Chowdhury et al.
JOURNAL OF INFECTION (2019)
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
James T. Peterson et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Decision-making for PCV in adults
John M. McLaughlin et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study
Xiaohui Sun et al.
EPIDEMIOLOGY AND INFECTION (2019)
Decreasing case fatality rate following invasive pneumococcal disease, North East England, 2006-2016
C. Houseman et al.
EPIDEMIOLOGY AND INFECTION (2019)
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control
Dominic Thorrington et al.
BMC MEDICINE (2018)
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study
Shamez N. Ladhani et al.
LANCET INFECTIOUS DISEASES (2018)
Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany
Ulrike Kuchenbecker et al.
PLOS ONE (2018)
Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
Jo Southern et al.
PLOS ONE (2018)
Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
Abdelmajid Djennad et al.
ECLINICALMEDICINE (2018)
Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia
Gertjan H. J. Wagenvoort et al.
VACCINE (2017)
Increased long-term mortality after survival of invasive pneumococcal disease: a population-based study
Hans Kristian Floeystad et al.
INFECTIOUS DISEASES (2017)
Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies
Myint Tin Tin Htar et al.
PLOS ONE (2017)
Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality
Julio A. Ramirez et al.
CLINICAL INFECTIOUS DISEASES (2017)
The impact of community-acquired pneumonia on the health-related quality-of-life in elderly
Marie-Jose J. Mangen et al.
BMC INFECTIOUS DISEASES (2017)
Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort
P. K. Myint et al.
EPIDEMIOLOGY AND INFECTION (2016)
Pneumococcal conjugate vaccine use in adults
Raul E. Isturiz et al.
EXPERT REVIEW OF VACCINES (2016)
Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease
G. J. Hughes et al.
EPIDEMIOLOGY AND INFECTION (2016)
Mortality reduction in adult community-acquired pneumonia in the UK (2009-2014): results from the British Thoracic Society audit programme
Priya Daniel et al.
THORAX (2016)
Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
Albert Jan van Hoek et al.
PLOS ONE (2016)
Pneumococcal Disease Prevention Among Adults Strategies for the Use of Pneumococcal Vaccines
Tamara Pilishvili et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2015)
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Chamira Rodrigo et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Pauline A. Waight et al.
LANCET INFECTIOUS DISEASES (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
Nick J. Andrews et al.
LANCET INFECTIOUS DISEASES (2014)
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
Albert Jan van Hoek et al.
VACCINE (2014)
Long-term Survival Following Pneumococcal Pneumonia
Barcleigh Sandvall et al.
CLINICAL INFECTIOUS DISEASES (2013)
Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial
Ron Dagan et al.
CLINICAL INFECTIOUS DISEASES (2013)
Acute pneumonia and the cardiovascular system
Vicente F. Corrales-Medina et al.
LANCET (2013)
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
Albert Jan van Hoek et al.
JOURNAL OF INFECTION (2012)
Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population
A. H. W. Bruns et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
Elizabeth Miller et al.
LANCET INFECTIOUS DISEASES (2011)
Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study
Stefan Flasche et al.
PLOS MEDICINE (2011)
Pneumonia in the immunocompetent patient
J. H. Reynolds et al.
BRITISH JOURNAL OF RADIOLOGY (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
Jaime L. Rubin et al.
VACCINE (2010)
The incidence of pneumonia using data from a computerized general practice database
P. R. Myles et al.
EPIDEMIOLOGY AND INFECTION (2009)
Increasing hospital admissions for pneumonia, England
Caroline L. Trotter et al.
EMERGING INFECTIOUS DISEASES (2008)
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
Cynthia G. Whitney et al.
LANCET (2006)
The current burden of pneumococcal disease in England and Wales
A Melegaro et al.
JOURNAL OF INFECTION (2006)
A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting
M Hussain et al.
EPIDEMIOLOGY AND INFECTION (2005)
Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care
E Hak et al.
FAMILY PRACTICE (2005)
Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales
A Melegaro et al.
VACCINE (2004)
Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community
J Macfarlane et al.
THORAX (2001)
分享论文
